Journal: iScience

Article Title: Oleic acid triggers metabolic rewiring of T cells poising them for T helper 9 differentiation

doi: 10.1016/j.isci.2024.109496

Figure Lengend Snippet:

Article Snippet: Anti-human IL-22; Vio® B515; Isotype Human; Clone REA466 , Miltenyi Biotec , Cat#130-108-096; RRID: AB_2652431.

Techniques: Activation Assay, Control, Isolation, Recombinant, Modification, Staining, cDNA Synthesis, Gene Expression, Software

Journal: STAR Protocols

Article Title: Protocol for large scale whole blood immune monitoring by mass cytometry and Cyto Quality Pipeline

doi: 10.1016/j.xpro.2022.101697

Figure Lengend Snippet:

Article Snippet: Anti-Human IL-23 p19 (23dcdp)-161Dy—100 Tests , Standard BioTools , Cat3161010B.

Techniques: Purification, Recombinant, Staining, Saline, Antibody Labeling, Software, Cell Counting

Journal: bioRxiv

Article Title: De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling test-time compute

doi: 10.1101/2025.05.28.656709

Figure Lengend Snippet: a. On-cell K D measurements for titrations of anti-CXCR4 designs on PathHunter CXCR4 cell line. Error bars are 95% CI for bar plot and SD for binding trace. Weak binders for which an accurate on-cell KD was not calculable are excluded. Binding control is shown in dark grey. b. On-cell K D measurements and titrations of anti-CXCR7 designs on PathHunter CXCR7 cell line as shown in panel (a). c. Binding trace of top anti-CXCR4 design (left) and anti-CXCR7 design (right) against their respective PathHunter target positive (orange) and background (grey) cell line. d . On-cell K D for anti-CXCR4 designs against additional disease-relevant CXCR4 expressing cell lines (Ramos and Jurkat) e. Single-point binding signal for anti-CXCR4 and anti-CXCR7 at their highest expressed concentration against both CXCR4 and CXCR7 cell lines to evaluate on- and off-target binding. f. Developability heatmaps for CXCR4-targeting (top) and CXCR7-targeting (bottom) designs, showing production yield in ExpiCHO post 1-step purification, monomericity by SEC, and polyspecificity by BVP ELISA normalized to Ustekinumab. Designs passing the criteria are denoted by a brown dot. Designs meeting all developability criteria and an on-cell K D threshold of <50 nM are highlighted by an orange box.

Article Snippet: BVP scores were determined by normalizing raw absorbance to control wells with no test antibody (i.e. BVP-only control), and normalized to Trastuzumab (ICH-4031; Ichor Bio) or Ustekinumab (HY-P9909; MedChem Express) scores assayed concurrently.

Techniques: Binding Assay, Control, Expressing, Concentration Assay, Purification, Enzyme-linked Immunosorbent Assay

Journal: Cell reports

Article Title: Single-cell RNA sequencing identifies a population of human liver-type ILC1s

doi: 10.1016/j.celrep.2022.111937

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: IL22 APC (REA466) , Miltenyi , RRID: AB_2652429; Cat#130-106-959.

Techniques: Blocking Assay, Recombinant, Clinical Proteomics, Nucleic Acid Electrophoresis, Software, Inverted Microscopy